Dr. Yaro Muñoz

🚨 Retzius-sparing RARP: better early continence, worse long-term cancer control in the first randomized trial 10-yr readout 🚨 @EurUrolOncol, post hoc analysis of an RCT 👥 120 men, NCCN low/intermediate risk PCa, randomized 1:1 RS vs anterior RARP ⏱️ Median f/u 77 mo, 20 progression events (BCR and/or any additional tx) ✅ 5-yr PFS: 80.2% RS vs 91.1% anterior (p=0.01) ✅ 10-yr PFS: 50.5% vs 82.0% ✅ Adjusted for CAPRA-S: HR 2.64 for progression w/ RS (95% CI 1.01 to 6.91) ⚠️ Signal held in negative-margin pts only: 5-yr 81.1% vs 96.1% (p=0.042), so not just a margin story ⚠️ RS arm had more pT3 (45% vs 23%) and numerically more PSMs (25% vs 13%) ⚠️ Small trial, oncology not the original endpoint, only 9 pts at risk at 10 yr, and the 2 surgeons had done just 60 RS cases total. Expert series suggest ~100 to flatten the learning curve 🎯 First randomized long-term evidence that the oncologic equivalence of RS RARP cannot be assumed. 👉Not a final verdict on RS in high-volume hands 🔗 doi.org/10.1016/j.euo.2026.0… @AmerUrological @UroOnc @SUO_YUO @PCF_Science @PCFnews @UrologyTimes @urotoday

🚨23 years of PSA screening in @NEJM 🚨 👉ERSPC RCT of >162k patients 📅Median 23 year f/u PSA screening lead to... 📉 #prostatecancer mortality by 13% ✅1 death prevented for every 456 men invited for screening or 12 diagnosed w/ PCa 📉Risk of advanced PCa by 34% ⭐️Benefit continues to rise over time as harm-benefit ratio improves 🔗shorturl.at/ajgNN @PCF_Science @PCFnews @urotoday @UrologyTimes @renalandurology @UroOnc